Class effects of SGLT2 inhibitors on cardiorenal outcomes

Table 1 Renal drug guidelines, entry criteria, mean estimated glomerular filtration rate, and composite outcome definitions in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials

Trial	FDA indicated guidelines	Study renal entry criteria			Results
Trial	Minimum recommended eGFR	eGFR minimum	eGFR equation	Additional renal criteria	Mean eGFR	Composite renal outcome
DECLARE-TIMI 58	45	N/A	CKD-EPI	CrCl 60 mL/min (Cockroft-Gault equation)	85.2	≥ 40% reduction in eGFR to < 60, ESRD (dialysis ≥ 90 days, transplant or sustained eGFR < 15), or renal/CV death
CANVAS	45	30	MDRD	N/A	76.5	≥ 40% reduction in eGFR, RRT (transplant, chronic dialysis, or sustained eGFR < 15), or renal death
EMPA–REG OUTCOME	45	30	MDRD	N/A	74	Doubling of serum Cr with eGFR ≤ 45, RRT, or renal death
CREDENCE	45	30	CKD-EPI	UACR 300–5000	56.2	Doubling of serum Cr, ESRD (eGFR < 15, dialysis, or renal transplant), renal/CV death

All eGFRs are in mL/min/1.73 m²
eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease, CKD-EPI chronic kidney disease epidemiology collaboration, RRT renal-replacement therapy, ESRD end-stage renal disease, CV cardiovascular, CrCl creatinine clearance, Cr creatinine, UACR urinary albumin-creatinine ratio in mg/g

ISSN: 1475-2840